bevacizumab,olaparib
astrazeneca,merck,roche
['lba29']
#esmo22 lba29 no difference in os in the itt analysis (hr = 0.92) but os prolonged in pts with hrd+ disease (mos: 75.2 vs 57.3 mo). hrd- population did not benefit from the combo. updated mpfs in hrd+ 46.8 vs 17.6 mo, hr 0.41 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to help clinicians & educators manage the oncology information deluge